Skip to main content
Premium Trial:

Request an Annual Quote

Sage-N Research to Market Nonlinear Dynamics Software Under New Deal


Sage-N Research and Nonlinear Dynamics have signed a co-marketing deal to combine their respective product offerings to provide a workflow solution for proteomics laboratories.

Under the terms of the agreement, Sage-N Research will market Nonlinear Dynamics' Progenesis LC-MS label-free quantification software alongside its Sorcerer proteomics platform.

Ali Pervez, vice president of marketing and sales at Sage-N Research, said his firm believes that the Progenesis software will help tackle problems associated with “achieving superior quantitation” which he described as a common “rate-limiting step” for customers.

Mark Bennett, general manager of Nonlinear Dynamics’ US operations, added that the Sorcerer platform will provide a storage resource for his company’s customers to store the large quantities of data they produce.

Sorcerer combines proprietary hardware with a range of proprietary post-processing software tools that enable users to identify and characterize low-abundance phospho-proteins and post-translational modifications. The tool also includes server-based solutions for storage and back-up of datasets.

The Progenesis software can be used for both differential protein expression and protein characterization applications and enables users to quantify peptides and proteins independently of identification.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.